CJD-tainted blood- and plasma-derivatives should be recalled, FDA ad hoc committee recommends.

CJD-TAINTED BLOOD- AND PLASMA-DERIVED PRODUCTS SHOULD BE WITHDRAWN, FDA's Ad Hoc Advisory Committee on Creutzfeldt- Jakob Disease decided at its inaugural meeting June 22 in Bethesda, Md. On a vote of 12-0 with one abstention the committee determined that blood components "from donors who are diagnosed with CJD" should be withdrawn; the vote shifted to 10-2 with one abstention on the withdrawal of "implicated plasma derivatives."